Human therapeutic uses of BPI protein products
AssigneeXoma Corporation
InventorsNadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
Claims8
A method for treatment of sepsis or septic shock in humans exposed to bacterial endotoxin in circulation comprising administering to said human a bactericidal/permeability-increasing (BPI) protein product in an amount effective to alleviate an endotoxin mediated effect.
Dependencies are inferred from the claim text.